Neurocrine’s schizophrenia drug succeeds at phase 2, but dosing questions remain 29-Aug-2024 By Helen Albert Neurocrine Biosciences has achieved late-stage success with muscarinic M4 selective agonist in schizophrenia.
BMS buys Karuna Therapeutics for $14 billion in deal that includes schizophrenia treatment 02-Jan-2024 By Liza Laws Bristol Myers Squibb has announced it has acquired Karuna Therapeutics, Inc., for a total equity value of $14 billion or $12.7 billion net of estimated cash.
Charles River forms drug discovery pact with CNS-focused biotech 17-Feb-2020 By Nick Taylor Charles River enters into partnership with Karuna to discover central nervous system therapeutics.
Sosei Heptares pulls dementia trial to minimize CRO expenditure 18-Nov-2019 By Nick Taylor Sosei Heptares withdraws Phase II dementia with Lewy bodies trial to reduce spending on contract research while clinical activity is suspended.